Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

Late Development

Late Development

“Our goal is to evolve the next wave of cancer therapies into comprehensive regimens that combine several approaches tailored to patients’ individual needs.”

Craig Tendler, M.D.

Vice President, Late Development and Global Medical Affairs for Oncology

Delivering on Discovery’s Potential

Janssen Oncology’s late-stage development efforts are integrated with research and commercialization to form teams intensely focused on specific cancers with fully dedicated groups for each compound. Our global research and development capabilities have produced a legacy of transformational therapies for tumor types where there remains a great need for new treatment options.

For 30 years, we have been pioneering innovations in oncology, with a distinguished and robust portfolio of novel therapies addressing significant unmet needs. We have achieved multiple health authority milestones, including Breakthrough Therapy Designations and Priority Reviews from the U.S. Food and Drug Administration and other regulators and PRIME Designation from the European Medicines Agency.  At the Janssen Pharmaceutical Companies of Johnson & Johnson, our team of world-class experts in oncology development has access to tremendous global and local resources, including market access, and regulatory and medical affairs.

Oncology

Oncology

Human lung bronchioalveolar carcinoma cell